Bertoglio, Federico http://orcid.org/0000-0001-6477-1785
Meier, Doris
Langreder, Nora
Steinke, Stephan http://orcid.org/0000-0001-8559-954X
Rand, Ulfert http://orcid.org/0000-0002-5946-4921
Simonelli, Luca
Heine, Philip Alexander
Ballmann, Rico
Schneider, Kai-Thomas
Roth, Kristian Daniel Ralph
Ruschig, Maximilian
Riese, Peggy
Eschke, Kathrin
Kim, Yeonsu
Schäckermann, Dorina
Pedotti, Mattia
Kuhn, Philipp
Zock-Emmenthal, Susanne
Wöhrle, Johannes http://orcid.org/0000-0001-5350-5596
Kilb, Normann
Herz, Tobias
Becker, Marlies
Grasshoff, Martina
Wenzel, Esther Veronika
Russo, Giulio http://orcid.org/0000-0003-4099-6968
Kröger, Andrea
Brunotte, Linda http://orcid.org/0000-0001-8074-7400
Ludwig, Stephan http://orcid.org/0000-0003-4490-3052
Fühner, Viola
Krämer, Stefan Daniel http://orcid.org/0000-0002-0071-9344
Dübel, Stefan http://orcid.org/0000-0001-8811-7390
Varani, Luca
Roth, Günter
Čičin-Šain, Luka http://orcid.org/0000-0003-3978-778X
Schubert, Maren
Hust, Michael http://orcid.org/0000-0003-3418-6045
Article History
Received: 5 June 2020
Accepted: 28 January 2021
First Online: 11 March 2021
Competing interests
: The authors declare a conflict of interest. The authors F.B., D.M., N.L., S.S., P.A.H., R.B., M.R., K.T.S., K.D.R.R., S.Z.-E., M.B., V.F., S.T., M.S. and M.H. submitted a patent application on blocking antibodies against SARS-CoV-2. The patent was licensed to CORAT Therapeutics GmbH, a company founded by YUMAB GmbH. S.D. and M.H. are shareholders of YUMAB GmbH.